KONINKLIJKE PHILIPS NV
No enriched coverage for $PHG in the last 7 days.
No SEC Form 4 filings for $PHG in the last 30 days.
See all $PHG insider activity →Philips and 41 partners launch a 5-year, EUR 27.6M research project to improve cardiac care. The EXIT-CVD project will involve 22 studies with 14,000+ patients across 17 countries, focusing on early detection, personalized interventions, and advanced therapies. Patient enrollment begins this month, with the goal of transforming cardiovascular disease management.
Royal Philips (NYSE: PHG) (AEX: PHIA) launched the Philips Sonicare Next-Generation DiamondClean 9900 Prestige toothbrush on Amazon.ca. The AI-powered toothbrush offers real-time brushing guidance and is priced at $499.99 CAD. Philips claims it removes 2000% more plaque and delivers 1500% healthier gums than manual toothbrushes in 6 weeks.
Philips (PHG) won a legal case against shareholders over its sleep-apnea device recall. The Dutch court rejected claims of misleading disclosures and slow action by management. Philips ADRs closed at $24.24, down 10.5% YTD. The recall cost Philips $2.96B in net losses over three years and a $1.1B settlement. The company returned to profitability in 2025 but earnings remain below pre-recall levels. The ruling does not address the US sales ban on Respironics devices, which remains a constraint.
Recent PHG coverage spans technology, financial news and regulation.
Long‑term research collaboration with modest budget; unlikely to affect near‑term price but may support future growth narrative.
Product availability and premium positioning could modestly support Philips Personal Health demand expectations, but it is not a financial guidance or scale-changing disclosure.
The court decision removes a governance uncertainty but does not change the underlying consent decree constraints on Respironics.
The ruling removes a legal cloud, likely supporting Philips' share price.
Potential short-term price pressure as the alert may trigger recalls or sales delays.
AlphAI scores every news story that mentions PHG with an AI model for sentiment and relevance, and aggregates insider trades from KONINKLIJKE PHILIPS NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
Philips and 41 partners launch a 5-year, EUR 27.6M research project to improve cardiac care. The EXIT-CVD project will involve 22 studies with 14,000+ patients across 17 countries, focusing on early detection, personalized interventions, and advanced therapies. Patient enrollment begins this month, with the goal of transforming cardiovascular disease management.
2 min readRoyal Philips (NYSE: PHG) (AEX: PHIA) launched the Philips Sonicare Next-Generation DiamondClean 9900 Prestige toothbrush on Amazon.ca. The AI-powered toothbrush offers real-time brushing guidance and is priced at $499.99 CAD. Philips claims it removes 2000% more plaque and delivers 1500% healthier gums than manual toothbrushes in 6 weeks.
3 min readPhilips (PHG) won a legal case against shareholders over its sleep-apnea device recall. The Dutch court rejected claims of misleading disclosures and slow action by management. Philips ADRs closed at $24.24, down 10.5% YTD. The recall cost Philips $2.96B in net losses over three years and a $1.1B settlement. The company returned to profitability in 2025 but earnings remain below pre-recall levels. The ruling does not address the US sales ban on Respironics devices, which remains a constraint.
2 min readA Dutch court dismissed shareholders' demands for an investigation into Philips' (AS:PHG) 2021 sleep apnea device recall, finding no grounds to question its policies or management practices. The ruling followed a review of internal documents, which showed the company's systems were based on international standards. Shareholders had alleged mismanagement and misinformation, but the court found no evidence of late disclosure of health risks.
2 min readThe FDA issued an alert about Philips' Lumify ultrasound system due to a software issue causing scanning delays. Reports link the issue to deaths and injuries, according to the FDA. Philips is involved in addressing the problem.
1 min readPhilips, GE HealthCare, and Siemens Healthineers face lawsuits from MR Access over alleged MRI patent infringements. The patents cover technology for improving MRI scan quality. MR Access, founded by MRI experts, seeks to license its patented technology.
2 min readPhilips (NYSE:PHG) launched its AI-powered Sonicare DiamondClean 9900 Prestige toothbrush on Amazon for $380. The device offers real-time brushing guidance and is part of the company's 2026 portfolio refresh. A survey by Philips found that 66% of Americans believe they miss areas while brushing. The company also released the DiamondClean 8500 model for $250.
1 min readRoyal Philips announced that two of its AI-enabled healthcare innovation projects, SYMPHONY and AI FORSchung, won ITEA Awards of Excellence 2026. SYMPHONY connects healthcare data and clinical workflows, while AI FORSchung focuses on AI-driven fiber-optic sensing data analysis. The awards were presented at the ITEA PO Days 2026 in Istanbul, Turkey. Philips is a global leader in health technology, listed on NYSE (PHG) and AEX (PHIA).
4 min readDutch exports to the US dropped 25% to €13B in H1 2024, due to 15% tariffs imposed by the Trump administration. Machinery, chemicals, and medical instruments saw significant declines. The US fell from the top five Dutch export destinations. Imports from the US rose 19%, driven by oil prices. Dutch companies are reclaiming €1B in duties, including €186M for Philips.
2 min readPhilips (NYSE:PHG, AEX: PHIA) launched the Lumea IPL 9900 Pro, an at-home hair removal device with audio guidance and motion tracking. The FDA-cleared device is priced at $699.95 and claims over 90% hair reduction after three treatments. Philips reported 2025 sales of EUR 18 billion.
1 min read
